Clinic
Jordan's Place Pediatrics, PA
Jordan's Place Pediatrics, PA was paid $5.57M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.
33Billing provider infoJORDAN'S PLACE PEDIATRICS, PA
SULPHUR SPRINGS, TX 75482
SULPHUR SPRINGS, TX 75482
33aNPI1245419431assigned 10/24/2007
33bProvider typePrimary Care Clinic/Center
28Total paid$5.57M
24GClaims215,519
24DCodes billed83
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Texas
Rank by total paid#2 of 180
Median peer was paid$25K
This provider vs. median222×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 259 | $6K | |
| 2019 | 466 | $13K | |
| 2020 | 10,890 | $233K | |
| 2021 | 61,466 | $1.56M | |
| 2022 | 64,772 | $1.67M | |
| 2023 | 51,094 | $1.35M | |
| 2024incomplete | 26,572 | $748K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 42,578 | 34,344 | $1.37M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 14% | 6,908 | 5,517 | $784K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.9% | 10,083 | 8,503 | $438K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 7.8% | 5,975 | 5,880 | $433K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.2% | 5,167 | 5,128 | $403K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.2% | 5,854 | 4,697 | $343K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.2% | 3,444 | 3,415 | $292K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.7% | 25,744 | 10,599 | $262K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.7% | 10,122 | 9,340 | $204K |
| 96112 | 3.1% | 1,795 | 1,745 | $176K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.9% | 6,032 | 5,416 | $162K |
| 99429 | 2.2% | 3,801 | 3,739 | $124K |
71 more codes
| 99050 | 1.5% | 6,081 | $83K | |
| 30210 | 1.3% | 693 | $73K | |
| 87428 | <1% | 1,189 | $50K | |
| S8301 | Infection control supplies, not otherwise specified | <1% | 3,803 | $48K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 8,255 | $46K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,142 | $34K |
| 90461 | <1% | 7,558 | $29K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,094 | $28K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,197 | $26K |
| 69210 | <1% | 814 | $24K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,992 | $21K |
| 94010 | <1% | 756 | $18K | |
| 99381 | <1% | 403 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,037 | $13K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,184 | $12K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 251 | $10K |
| 80061 | Lipid panel | <1% | 876 | $10K |
| 99460 | <1% | 103 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 143 | $7K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 478 | $5K |
| 17110 | <1% | 40 | $3K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 35 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 42 | $2K |
| 81003 | <1% | 1,231 | $2K | |
| 58301 | <1% | 87 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 32 | $1K |
| 99383 | <1% | 13 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 13 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 765 | $1K |
| 83655 | <1% | 1,404 | $781.69 | |
| 85018 | <1% | 1,457 | $773.51 | |
| 90677 | <1% | 798 | $764.41 | |
| 17250 | <1% | 21 | $742.94 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $616.23 |
| 95117 | <1% | 63 | $512.82 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 453 | $437.60 |
| 90473 | <1% | 40 | $420.76 | |
| 96380 | <1% | 22 | $419.98 | |
| 81025 | <1% | 60 | $412.83 | |
| 96160 | <1% | 3,326 | $403.05 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,876 | $255.87 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 496 | $168.03 |
| 90686 | <1% | 2,400 | $125.73 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $85.06 |
| 90672 | <1% | 351 | $78.57 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 363 | $45.04 |
| 82947 | <1% | 13 | $41.35 | |
| 90697 | <1% | 658 | $2.16 | |
| 90651 | <1% | 1,303 | $0.05 | |
| 90381 | <1% | 39 | $0.04 | |
| 90621 | <1% | 521 | $0.03 | |
| 90380 | <1% | 14 | $0.02 | |
| 90648 | <1% | 3,090 | $0.01 | |
| 90696 | 0% | 788 | $0.00 | |
| 90716 | 0% | 922 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 557 | $0.00 |
| 90723 | 0% | 2,206 | $0.00 | |
| 96127 | 0% | 309 | $0.00 | |
| 86701 | 0% | 420 | $0.00 | |
| 90620 | 0% | 12 | $0.00 | |
| 90707 | 0% | 920 | $0.00 | |
| 90633 | 0% | 2,086 | $0.00 | |
| 90700 | 0% | 939 | $0.00 | |
| 90681 | 0% | 1,761 | $0.00 | |
| 99401 | 0% | 7,900 | $0.00 | |
| 90734 | 0% | 1,303 | $0.00 | |
| 90670 | 0% | 3,040 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 560 | $0.00 |
| 90715 | 0% | 762 | $0.00 | |
| 90710 | 0% | 841 | $0.00 | |
| 90685 | 0% | 589 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBARCLAY, SHERRI (PHYSICAN)